Efficacy of High Dose Radiotherapy in Post-operative Treatment of Glioblastoma Multiform - A Single Institution Report

• DOI: 10.7314/apjcp.2014.15.6.2793
• Publication Date: 2014-07-10T07:44:48Z
• Authors: Abdolazim Sedighi...; Ehsan Akbari Hamed; Kamal Mohamadian; Mohammad Abassi; Afsane Maddah Safaei; Tayebe Torkaman
• Keywords: Progression-free survival

Background: Glioblastoma multiform (GBM) is a highly aggressive tumor with median survival of approximately 14 months. Management consists maximal surgical resection followed by post-operative chemoradiation concurrent then adjuvant temozolamide. The standard radiotherapy dose 60Gy in 2-Gy fractions recommended the radiation therapy oncology group (RTOG). With vast majority recurrences occurring within previous irradiation field and poor outcome associated therapy, regimens designed to deliver higher doses improve local control enhance are needed. In this study, we report single institutional experience treatment 68 consecutive patients GBM, treated resection, given and/or chemotherapy. Results: Of 80 who entered completed course; 45 (66.2%) males 23 (33.8%) females mean age at diagnosis <TEX>$49.0{\pm}12.9$</TEX> (21-75) years. At follow up 19 months, 39 (57.3%) had evidence progression 36 (52.9%) died. over all for was 16 months free 6.02 All potential prognostic factors were analyzed evaluate their effects on overall survival. Age <TEX>${\leq}50$</TEX> year, chemotherapy extent surgery significant p values. We found lower rate among received (>60Gy). Higher improved (p=0.03). Despite increasing survival, elevation not significant. Conclusions: This study emphasize that (>60Gy) can potentially so strongly advise prospective multi centric studies role GBM patient outcome.